Abbott Share News - Latest Updates, Live News & More

More news about Abbott

Abbott India Limited Receives ₹2.40 Crore GST Penalty Order for Input Tax Credit Disallowance

Abbott India Limited has received a ₹2.40 crore GST penalty order from Mumbai East tax authorities for Input Tax Credit disallowance covering financial years 2018-19, 2019-20, 2021-22, and 2023-24. The company received the order on December 30, 2025, and plans to file an appeal, stating the demand is not maintainable. Abbott India expects no material impact on its financial operations from this penalty order.

24Dec 25

Abbott India Announces Board Changes for 2026

Abbott India Limited has announced significant changes to its board. Mr. Ambati Venu will resign as Director effective December 31, 2025, to pursue an external career opportunity. The company has approved the appointment of Mr. Vivek Mohan as Additional Non-Executive Director, effective January 1, 2026. Mohan brings extensive experience within Abbott, including his upcoming role as Abbott's Vice President, Established Pharmaceuticals, India. The company will seek shareholder approval for Mohan's appointment through a Postal Ballot Notice.

25Nov 25

Abbott India Announces Key Leadership Changes in HR Department

Abbott India Limited has announced the appointment of Ms. Vinutha Mufti as the new Director of Business Human Resources, effective December 16, 2025. She will replace Mr. Rajan Kalantre, who is transitioning to another Abbott affiliate. Ms. Mufti, with over 20 years of HR experience, has been with Abbott since 2015, holding various senior roles across the company's Pharmaceuticals and Nutrition businesses. Her appointment is expected to bring fresh perspectives to Abbott India's HR strategies, particularly in areas of managerial effectiveness, diversity, equity, and inclusion, and talent management.

24Nov 25

Abbott India Appoints New Managing Director

Abbott India Limited has announced the appointment of Ambati Venu as its new Managing Director, effective May 15, 2023, for a five-year term, subject to regulatory approvals. Venu, with over 29 years of experience in the pharmaceutical industry, previously served as Abbott India's Managing Director from 2016 to 2020 and most recently held the position of Group Vice President and Head of Established Pharmaceuticals Division for Abbott's global operations.

06Nov 25

ABB India Q3 Results: Revenue Rises 13.7% Despite Profit Decline

Abbott's Q3 FY2023 results show revenue growth of 13.7% to ₹3,310.00 crore, driven by strong performance in electrification and automation segments. However, net profit declined by 7.3% to ₹409.00 crore, falling short of analyst estimates. EBITDA decreased by 7.4% to ₹500.00 crore, with operating margin contracting to 15.1% from 18.5% year-on-year. The company faced challenges including cost pressures and an unfavorable product mix. New orders in the capital goods sector declined by approximately 20% year-on-year, excluding large one-off deals, indicating potential future headwinds.

28Oct 25

ABB India Boosts Local Drive Production with 25% Capacity Increase at Bengaluru Plant

ABB India has launched new variable speed drive modules at its Peenya factory in Bengaluru, increasing production capacity by 25% and reducing delivery times by up to 40%. The expansion features integrated robotics for automated production, catering to industries such as buildings, data centers, water, cement, and metals. This milestone marks two decades of drives production in India for ABB, following a recent ₹173.55 crore order for wind turbine converters from Siemens Gamesa Renewable Power.

15Oct 25

Abbott India Shareholders Approve Appointment of Darshan Gada as Director

Abbott India Limited concluded a postal ballot through e-voting, resulting in shareholders' approval of Darshan Gada's appointment as Director. The e-voting period ended on October 14, 2025, at 5:00 PM, with the resolution approved on the same day. Gada's appointment is effective from August 18, 2025. The company, listed under scrip code 500488 on BSE, disclosed the voting results in compliance with SEBI regulations.

25Sept 25

ABB India Shares Slump 35% in 12 Months Amid Operational Challenges

ABB India's stock has declined over 35% in the past year, underperforming peers like Siemens and Cummins India. The company faces operational challenges including sluggish decision-making, soft large-ticket business, margin pressures, and revenue shortfalls. Current P/E ratio is 57, a 23% discount to its 5-year average. Despite challenges, some analysts maintain cautious optimism, citing potential for faster order conversion and stronger project pipeline. Market sentiment suggests range-bound growth in the near term.

11Sept 25

Abbott India Seeks Shareholder Approval for Darshan Gada's Director Appointment

Abbott India Limited has initiated a postal ballot to appoint Darshan Gada as a Non-Executive Director. Gada, a 43-year-old Chartered Accountant with 21 years of finance experience, currently serves as Regional Finance Director at Abbott Healthcare Private Limited. The e-voting period is from September 15 to October 14, 2025, with results to be declared by October 16, 2025. Shareholders can access the Postal Ballot Notice on the company's website and KFin Technologies' e-voting platform.

29Aug 25

ABB India Secures ₹174 Crore Wind Turbine Converter Order, Reports Mixed Q3 Results

ABB India has won a ₹173.55 crore order from Siemens Gamesa for wind turbine converters and electrical cabinets, to be delivered from January to December 2026. The company's Q3 financial results show a 12.20% increase in revenue to ₹3,175.40 crore, but a 20.50% decrease in net profit to ₹351.70 crore. EBITDA also declined by 27.00% to ₹441.00 crore. Managing Director Sanjeev Sharma attributed the profit decline to forex volatility and one-time factors. Despite mixed results, ABB India's shares traded 0.76% higher at ₹5,039.00 following the order announcement.

26Aug 25

Abbott India Unveils FreeStyle Libre 2 Plus: Advanced Glucose Monitoring Device

Abbott India has introduced the FreeStyle Libre 2 Plus, a next-generation continuous glucose monitoring device for diabetes management. The device offers minute-by-minute glucose readings and customizable alarms for glucose levels outside the target range. This innovation aims to provide users with more precise data for better diabetes management decisions. Pricing and availability details have not been disclosed.

14Aug 25

Abbott India Shareholders Approve All Resolutions at 81st Annual General Meeting

Abbott India Limited held its 81st Annual General Meeting on August 13, 2025, via video conferencing. Shareholders approved all proposed resolutions, including the adoption of financial statements, declaration of a final dividend, reappointment of directors, appointment of secretarial auditors, ratification of cost auditor remuneration, and appointment of Mr. Kartik Rajendran as Director and Managing Director for five years. The voting process, conducted through NSDL, saw overwhelming support for all resolutions, with most receiving over 99% votes in favor. The company promptly submitted voting results and the scrutinizer's report to BSE Limited, demonstrating commitment to transparency and good corporate governance.

12Aug 25

Abbott India Reports Robust Q1 Performance with 11% Revenue Growth

Abbott India Limited announced robust Q1 FY2025 financial results. Revenue increased by 11.6% to ₹1,738.35 crore, while net profit grew 11.5% to ₹365.86 crore. EBITDA rose 14.1% to ₹445 crore, with the EBITDA margin improving to 25.63%. The company also appointed Mr. Darshan Gada as an Additional (Non-Executive) Director, effective August 18, 2025, subject to shareholder approval.

05Aug 25

ABB India Faces Industrial Project Slowdown, Targets 12-15% Profit Margin for 2025

ABB India reported a record order backlog exceeding Rs 10,000 crore, with 90% of business from the domestic market. The company is experiencing cyclical challenges in its systems order segment due to customer delays. Q2 results showed a 20.7% decrease in net profit to Rs 351.70 crore, while revenue grew 12.2% to Rs 3,175.40 crore. EBITDA margin fell to 13% from 19.2%. Despite challenges, ABB India sees strong demand in tier-1, tier-2, and tier-3 markets, particularly in infrastructure, real estate, and data centers. The company aims for 12-15% profit margins by 2025.

04Aug 25

ABB India Q2 Results: Revenue Grows 12% Amid Margin Pressure

ABB India's Q2 results show a 12% revenue growth to ₹3,175.00 crore, meeting expectations. However, profitability declined with EBITDA falling 24% to ₹414.90 crore and net profit decreasing by 21% year-on-year. EBITDA margin dropped to 13% from 19.2%. The company faced significant cost increases across various categories, including a 26% rise in raw material costs. Order inflow declined by 12% to ₹3,036.00 crore, but the order book grew 6% annually, crossing ₹10,000.00 crore. The board approved evaluating the potential incorporation of the Robotics division into a wholly-owned subsidiary. ABB India's stock closed 2.3% lower at ₹5,384.00 following the results.

02Aug 25

ABB India Q2 Profit Drops 21%, Revenue Grows Amid Margin Pressure

ABB India's Q2 financial results show a 12.2% year-over-year revenue increase to Rs 3,175.00 crore, beating estimates. However, net profit fell 21% to Rs 352.00 crore, missing analyst expectations. EBITDA decreased 23.7% to Rs 414.00 crore, with margins contracting from 19.2% to 13.00%. The company declared an interim dividend of Rs 9.77 per share. Despite challenges, 18 out of 31 analysts maintain a 'Buy' rating on the stock.

01Aug 25

Abbott India Pays Rs. 2 Lakh Penalty to RBI for Exceeding Foreign Investment Limits

Abbott India Limited has been penalized Rs. 2 lakh by the Reserve Bank of India for violating foreign exchange laws. The violation occurred when foreign investment in the company exceeded 75% without prior government approval. The RBI issued a Compounding Order on July 31, 2025, concluding the compounding process. Abbott India will deposit the penalty amount and can now receive foreign institutional investments up to the prescribed limit.

16May 25

Abbott India's Q4 Profit Surges, Beats Estimates

Abbott India Ltd reported strong Q4 financial results, surpassing market expectations. Net profit increased by 14.7% to ₹359.00 crore, revenue rose by 9% to ₹1,633.00 crore, and EBITDA grew by 15% to ₹439.00 crore. The company's stock gained nearly 4% following the announcement, reaching ₹31,500.00 per share.

15May 25

Abbott India: Q4 Profit Soars 28%, ₹475 Dividend Proposed

Abbott India's Q4 results show strong growth with net profit up 27.90% to ₹367.00 crore, revenue increasing 11.50% to ₹1,604.60 crore, and EBITDA rising 30.00% with margin expansion to 26.70%. The company has recommended a final dividend of ₹475.00 per share, subject to shareholder approval.